Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for diastolic hypertension with obesity
ChiCTR2200058619Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of semaglutide in essential hypertension and obesity (2 arms), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Diastolic blood pressure. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
03
Conditions
essential hypertensionobesity
Beyond the preview
Go deeper on ChiCTR2200058619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058619.